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evaluation of canagliflozin 300mg versus sitagliptin 100mg in patients inadequately 
controlled on MET+SU. Methods: Two 40-year simulations were performed using a 
validated economic model (ECHO-T2DM), differing only in the hypoglycemia disutility 
weights: (A) CADTH and (B) new estimates. Disutilities for T2DM-related complica-
tions and other adverse events were sourced from the literature. Data for patient 
characteristics, treatment effects (i.e. A1C, SBP, BMI, and cholesterol), and rates of 
adverse events were obtained from a previously reported 52-week trial, where canagli-
flozin 300mg demonstrated statistically superior A1C-lowering, as well as reductions 
in blood pressure and weight versus sitagliptin 100mg. Hypoglycemic event rates 
were similar. In the simulations, insulin (which has an excess risk of hypoglycemia) 
was added and titrated as necessary to maintain A1C < 7.0%. Results: Discounted 
QALYs for canagliflozin and sitagliptin were (A) 8.4 and 8.32; (B) 7.91 and 7.81. The 
higher QALYs associated with canagliflozin versus sitagliptin are largely attributable 
to the delay in the need for insulin for canagliflozin-treated patients. The contribu-
tion of hypoglycemic events to these total QALY differences was greater in scenario 
B (20.8%) than scenario A (2.3%). ConClusions: These results illustrate the need to 
carefully consider downstream assumptions in economic evaluations. Using the older 
values yielded 20% fewer net QALYs, implying that the corresponding ICER would be 
approximately 25% greater.
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objeCtives: Risk of the outcome is a mathematical determinant of the absolute 
treatment benefit of an intervention. While substantial risk heterogeneity can lead 
to clinically important differences in treatment effect, the degree to which risk varies 
within randomized clinical trials (RCTs) is largely unknown. Methods: We selected 
all RCTs that had greater than ~1000 enrollees and clinical outcomes from several 
sources (NHLBI, NIDDK, Trials journal). We derived Cox or logistic regression models 
using established risk factors blinded to treatment assignment. Risk heterogene-
ity was evaluated using the extreme quartile risk ratio (EQRR, the ratio of outcome 
rates in the lowest risk quartile to that in the highest). Skewness was evaluated with 
median to mean risk ratio (MMRR, the ratio of risk in the median risk patient to the 
average). Results: We describe the distributions of 34 unique risk analyses from 25 
heterogeneous large trials. Overall event rates across studies ranged from 3% to 63% 
(median= 15%, interquartile range [IQR] 10% to 23%). The number of established risk 
factors included in each risk model ranged from 4 to 32 (median= 9, IQR 7 to 11); events 
per variable ranged from 13 to 1515 (median= 46, IQR 32 to 66). Models had estimated 
C-statistics of 0.58 to 0.81 (median 0.69, IQR 0.65 to 0.73). EQRR ranged from 1.8 to 21.6 
(median= 4.1, IQR 3.0 to 5.5). The MMRR ranged from 0.5 to 1.0 (median= 0.87, IQR 0.80 
to 0.89). The model C-statistic and the outcome rate of the trial determined the EQRR 
(r-squared= 0.87) and the MMRR (r-square= 0.81). ConClusions: Clinically significant 
risk heterogeneity is common even in phase 3 “efficacy” trials. The typical patient is 
generally at lower risk than reflected by the trial summary results. A risk stratified 
approach to trial analysis is feasible and may be most clinically informative where 
the outcome is predictable and uncommon.
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objeCtives: To present an efficient new methodology to calculate cost and effects 
of alternative interventions for Diabetes Mellitus (DM), and to validate this approach 
by comparing cost-effectiveness results when identical interventions for DM are 
simulated by this Markov model (DELTA) or by a well-known Micro-Markov model 
(CARDIFF). Methods: The Markov model (DELTA) deals with multiple competing 
events; complications are modeled as individual Markov chains. By creating a dynamic 
link between the life table and the subdiseases, any change in the individual Markov 
chains is propagated throughout the entire model. Advantage of this approach is a 
considerable decrease in computational time. In order to test the validity of the DELTA 
model and its applicability in modeling interventions and treatment sequences in 
T2DM, cost-effectiveness results were compared with published outcomes predicted 
by the CARDIFF model. Similar treatment sequences were applied as well as identical 
key data sources for predicting the occurrence of diabetes related events (equations 
UKPDS Outcomes model), quality of life effects attached to BMI changes and hypo-
glycemia, and inputs related to drug- and health care costs. Results: Incremental 
life-years gained (LYG), discounted incremental costs, incremental QALYs and ICUR 
in the Cardiff and DELTA models are 0.050 LYG, £1,246, 0.467 QALY, £2,671/QALY, and 
0.031 LYG, £1,021, 0.555 QALY, £1,841/QALY, respectively. Differences between model 
outcomes may be explained by the underlying independency assumptions of the 
DELTA model. ConClusions: The point estimates obtained by both models using 
similar scenarios seem to resonate quite well. However, further research is needed 
to substantiate the observed differences in outcomes. Additional insight can be pro-
vided by comparing the confidence intervals around the estimates, which will be 
incorporated shortly. It seems the DELTA approach offers a flexible way to model 
multiple diseases simultaneously. The loss of subtlety and necessary assumptions 
may outweigh the gains in clarity and computational speed.
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ing will drive up the quality and efficiency of pharmacoepidemiological database 
studies.
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objeCtives: Using observational databases to calculate vaccination rate is challeng-
ing because of limited continuous enrollment and loss to follow-up. The objective of 
this study was to apply the concept of survival analysis in estimating rate of pneumo-
coccal vaccination among adults with the high-risk medical conditions included in the 
ACIP (Advisory Committee on Immunization Practices) recommendations. Methods: 
This was a retrospective cohort study using a large administrative claims database. 
The study cohort was 19-64 years old adults with newly diagnosed high-risk condi-
tions (HIV/AIDS, diabetes, asplenia, chronic lung disease, chronic renal disease, chronic 
heart disease, organ transplant, cochlear implant, cancer, chronic liver disease and 
alcoholism) during 2007 to 2010 and had at least three years of continuous enrollment. 
Subjects were followed from the initial diagnosis date to the end of enrollment or 
2011. Cox proportional hazard model was used to analyze the association of high-
risk medical conditions with pneumococcal vaccination after controlling potential 
confounders. Survival curves were estimated from the Cox model. Results: A total of 
946,898 eligible subjects were followed for a total of 2,358,563 person-years, of which, 
71,298 subjects received pneumococcal vaccine. The overall pneumococcal vaccination 
rate was 3.023/100 person years (95%CI= 3.001, 3.045). Pneumococcal vaccination rate 
was the highest in HIV/AIDS patients (16.499/100 person years, 95%CI= (15.374,17.683)) 
followed by diabetes patients (4.520/100 person years, 95%CI= (4.466,4.574)) and was 
the lowest in alcoholism patients (1.042/100 person years, 95%CI= (0.953,1.137)). After 
controlling potential confounders, high-risk conditions had a significant association 
with pneumococcal vaccination. Compared to patients with alcoholism, HIV/AIDS 
patients were 11 times more likely to receive pneumococcal vaccination (HR= 11.964, 
95%CI= (10.696,13.382), p< 0.0001). ConClusions: Pneumococcal vaccination rate 
was more accurately analyzed by applying survival analysis because a larger and 
more representative sample was constructed and loss to follow-up was taken into 
account. Study suggests pneumococcal vaccination rate was low in adults with newly 
diagnosed high-risk conditions.
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objeCtives: Open data sharing for large-scale studies is an expensive and resource-
wasteful approach that does not scale well with participating sites. Critically, some 
data simply cannot be shared due to privacy concerns and/or risk of re-identifica-
tion. We pursue distributed computation that only shares data derivatives, such as 
statistical summaries, as a notable alternative allowing data holders to maintain 
control over data access. Privacy protection, if implemented via the differential privacy 
framework, can quantify and controllably reduce the risk of sharing the results of 
computations on private data. Unfortunately, it can impair the quality of statistical 
estimates at a single site. Using structural MRI data we present a distributed differ-
entially private classifier that greatly improves the accuracy. Methods: We used a 
combined MRI dataset from four separate schizophrenia studies conducted at Johns 
Hopkins University (JHU), the Maryland Psychiatric Research Center (MPRC), the 
Institute of Psychiatry, London, UK (IOP), and the Western Psychiatric Institute and 
Clinic at the University of Pittsburgh (WPIC). The sample comprised 198 schizophre-
nia patients and 191 matched healthy controls. We trained differentially private clas-
sifiers on these data using a method that minimizes a perturbed version of the SVM 
classifier. The outputs of these classifiers were used to train a logistic regression 
classifier. A combined SMVs plus logistic regression classifier was tested for accu-
racy. Results: Using 100 random splits of data into 70% training and 30% validation 
groups followed by splitting the training set into 11 sites of 24/25 subjects each, we 
assessed classification accuracy at each site and of combination per split. Average 
site-accuracy was below 78%, while our combined classifier averaged to 96%: sub-
stantial and significant improvement with Bonferroni-corrected p-values below 
1.8e-33. ConClusions: Our approach provides a way to enable use of distributed 
big data while still providing privacy and thus a much larger effective sample size.
ReseaRch on Methods – Modeling Methods
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objeCtives: Differences in the frequency and severity of hypoglycemic episodes 
associated with alternative treatments often contribute significantly to differences 
in QALYs (the denominator of the cost-effectiveness ratio). The 2013 T2DM CADTH 
report examining third-line therapy used disutility values from studies conducted 
before 2009 based on small samples. A new study with over 1,600 individuals with 
T2DM (including Canadian respondents) found disutility estimates that were mean-
ingfully greater (e.g. 0.005 versus 0.000004767 per non-severe hypoglycemic event). 
This analysis examined the impact of these alternative estimates on QALYs in an 
